Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL/6 mice immunized with prion protein peptides.
Prion diseases are associated with the conversion of the normal host cellular prion protein to an abnormal protease-resistant (PrPres) associated with infectivity. No specific immune response against prions develops during infection due to the strong tolerance to cellular prion protein. We examined the protective potential on prion diseases of immune responses elicited in C57BL/6 mice with PrP peptides 98-127 (P5) or 158-187 (P9) with CpG. After immunization, P5-treated mice developed high titer and long-lasting Abs, and P9-treated mice developed transient IFN-gamma secreting T cells and poor and variable Ab responses. Both treatments impaired early accumulation of PrPres in the spleen and prolonged survival of mice infected with 139A scrapie. Additional P9 boosts after 139A infection sustained the T cell response and partially inhibited PrPres early accumulation but did not improve the survival. Surprisingly, when P9 injections were started 1 mo after infection and repeated subsequently, specific T cell and Ab responses were impaired and no beneficial effect on prion disease was observed. After a single injection of P9, the number of IFN-gamma secreting CD4+ T cells was also reduced in mice 8- to 10-wk postinfection compared with healthy mice. In vivo and in vitro removal of CD4+CD25+ T cells restored the T cell response to P9 in infected mice. In conclusion, CD4+ T cells as well as Abs might participate to the protection against scrapie. Of importance, the peripheral accumulation of PrPres during infection negatively interferes with the development of T and B cell responses to PrP and regulatory T cells might contribute to this phenomenon.
Sacquin
Antoine
A
Institut National de la Santé et de la Recherche Médicale UMRS 893, Paris, Université Pierre et Marie Curie Univ Paris 06, Hôpital Saint-Antoine, Paris, France.
Bergot
Anne Sophie
AS
Aucouturier
Pierre
P
Bruley-Rosset
Martine
M
D016915:AIDS Vaccines; D000818:Animals; D000906:Antibodies / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000276:immunology*; D011328:Prions / Q000276:immunology* / Q000472:pathogenicity; D012608:Scrapie / Q000145:classification / Q000276:immunology* / Q000473:pathology*; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
D016915:AIDS Vaccines; D000906:Antibodies; D010455:Peptides; D011328:Prions; C053473:VaxSyn HIV-1 (gp160) vaccine; D007371:Interferon-gamma